Silver Book Fact
Lucentis to treat wet age-related macular degeneration (AMD)
An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.
Rosenfeld P, Brown D, Heier J, Boyer D, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006; 355(14): 1419-31. http://content.nejm.org/cgi/content/abstract/355/14/1419